Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junsung Choi

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Gastrointestinal Oncology|July 13, 2018
Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolizationJessica M Frakes, Yazan A Abuodeh, Arash O Naghavi, et al.
Annals of Surgical Oncology|November 25, 2015
Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver MetastasesMarybeth S Hughes, Jonathan Zager, Mark Faries, et al.
World Journal of Gastroenterology|January 7, 2017
Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolizationYazan Abuodeh, Arash O Naghavi, Kamran A Ahmed, et al.
Journal of the National Cancer Institute|April 25, 2014
Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial resultsMark D Hurwitz, Pejman Ghanouni, Sergey V Kanaev, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 26, 2018
Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective StudyAlexandra Gangi, Jehan Shah, Nathan Hatfield, et al.
Journal of Cancer Research and Clinical Oncology|December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Gastrointestinal Oncology|July 13, 2018
Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolizationJessica M Frakes, Yazan A Abuodeh, Arash O Naghavi, et al.
Annals of Surgical Oncology|November 25, 2015
Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver MetastasesMarybeth S Hughes, Jonathan Zager, Mark Faries, et al.
World Journal of Gastroenterology|January 7, 2017
Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolizationYazan Abuodeh, Arash O Naghavi, Kamran A Ahmed, et al.
Journal of the National Cancer Institute|April 25, 2014
Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial resultsMark D Hurwitz, Pejman Ghanouni, Sergey V Kanaev, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 26, 2018
Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective StudyAlexandra Gangi, Jehan Shah, Nathan Hatfield, et al.
Journal of Cancer Research and Clinical Oncology|December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
Pageof 5